The Filings Report

Incyte Genomics Inc

INCYNasdaqCIK 879169Healthcare / Diagnostics & Researchfiscal year ends December67 quarters since 2010

Revenue, Q3 FY2026
$1.6B
+14.0% on Q3 FY2025
Net income
−$785M
−285.0% on Q3 FY2025
Free cash flow
—
no year-earlier figure
Diluted EPS
$-3.86
−282.9% on Q3 FY2025
Revenue, TTM
$6.0B
trailing four quarters
Net margin, TTM
6.7%
net income $403M
Free cash flow, TTM
—
Cash and equivalents
$3.3B
long-term debt —, Sep 30, 2026
Shares, 12-month change
+3.8%
204M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$24.5B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Incyte Genomics Inc reported revenue of $1.6B, +14.0% on Q3 FY2025, and net loss of $785M (−285.0%). Operating margin was −45.5%. Diluted earnings per share were $-3.86.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$1B$0$1B$2BQ4'22, Revenue: $927MQ4'22, Net income: $28MQ4'22Q1'23, Revenue: $809MQ1'23, Net income: $22MQ1'23Q2'23, Revenue: $955MQ2'23, Net income: $204MQ2'23Q3'23, Revenue: $919MQ3'23, Net income: $171MQ3'23Q4'23, Revenue: $1.0BQ4'23, Net income: $201MQ4'23Q1'24, Revenue: $881MQ1'24, Net income: $170MQ1'24Q2'24, Revenue: $1.0BQ2'24, Net income: −$445MQ2'24Q3'24, Revenue: $1.1BQ3'24, Net income: $106MQ3'24Q4'24, Revenue: $1.2BQ4'24, Net income: $201MQ4'24Q1'25, Revenue: $1.1BQ1'25, Net income: $158MQ1'25Q2'25, Revenue: $1.2BQ2'25, Net income: $405MQ2'25Q3'25, Revenue: $1.4BQ3'25, Net income: $424MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: $299MQ4'25Q1'26, Revenue: $1.3BQ1'26, Net income: $303MQ1'26Q2'26, Revenue: $1.7BQ2'26, Net income: $586MQ2'26Q3'26, Revenue: $1.6BQ3'26, Net income: −$785MQ3'26−$1B$0$1B$2BQ4'22, Revenue: $927MQ4'22, Net income: $28MQ1'23, Revenue: $809MQ1'23, Net income: $22MQ1'23Q2'23, Revenue: $955MQ2'23, Net income: $204MQ3'23, Revenue: $919MQ3'23, Net income: $171MQ3'23Q4'23, Revenue: $1.0BQ4'23, Net income: $201MQ1'24, Revenue: $881MQ1'24, Net income: $170MQ1'24Q2'24, Revenue: $1.0BQ2'24, Net income: −$445MQ3'24, Revenue: $1.1BQ3'24, Net income: $106MQ3'24Q4'24, Revenue: $1.2BQ4'24, Net income: $201MQ1'25, Revenue: $1.1BQ1'25, Net income: $158MQ1'25Q2'25, Revenue: $1.2BQ2'25, Net income: $405MQ3'25, Revenue: $1.4BQ3'25, Net income: $424MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: $299MQ1'26, Revenue: $1.3BQ1'26, Net income: $303MQ1'26Q2'26, Revenue: $1.7BQ2'26, Net income: $586MQ3'26, Revenue: $1.6BQ3'26, Net income: −$785MQ3'26

Net income losses drawn in red.

Free cash flow
$0$100M$200M$300MQ4'22, Free cash flow: $262MQ4'22Q1'23Q2'23Q3'23Q4'23Q1'24Q2'24Q3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26$0$100M$200M$300MQ4'22, Free cash flow: $262MQ1'23Q3'23Q1'24Q3'24Q1'25Q3'25Q1'26Q3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3B$4BQ4'22, Cash and equivalents: $3.0BQ4'22Q1'23, Cash and equivalents: $2.8BQ1'23Q2'23, Cash and equivalents: $3.1BQ2'23Q3'23, Cash and equivalents: $3.2BQ3'23Q4'23, Cash and equivalents: $3.2BQ4'23Q1'24, Cash and equivalents: $3.3BQ1'24Q2'24, Cash and equivalents: $987MQ2'24Q3'24, Cash and equivalents: $1.3BQ3'24Q4'24, Cash and equivalents: $1.7BQ4'24Q1'25, Cash and equivalents: $1.9BQ1'25Q2'25, Cash and equivalents: $2.0BQ2'25Q3'25, Cash and equivalents: $2.5BQ3'25Q4'25, Cash and equivalents: $3.1BQ4'25Q1'26, Cash and equivalents: $3.5BQ1'26Q2'26, Cash and equivalents: $4.0BQ2'26Q3'26, Cash and equivalents: $3.3BQ3'26$0$1B$2B$3B$4BQ4'22, Cash and equivalents: $3.0BQ1'23, Cash and equivalents: $2.8BQ1'23Q2'23, Cash and equivalents: $3.1BQ3'23, Cash and equivalents: $3.2BQ3'23Q4'23, Cash and equivalents: $3.2BQ1'24, Cash and equivalents: $3.3BQ1'24Q2'24, Cash and equivalents: $987MQ3'24, Cash and equivalents: $1.3BQ3'24Q4'24, Cash and equivalents: $1.7BQ1'25, Cash and equivalents: $1.9BQ1'25Q2'25, Cash and equivalents: $2.0BQ3'25, Cash and equivalents: $2.5BQ3'25Q4'25, Cash and equivalents: $3.1BQ1'26, Cash and equivalents: $3.5BQ1'26Q2'26, Cash and equivalents: $4.0BQ3'26, Cash and equivalents: $3.3BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Incyte Genomics Inc income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 28, 2026Q1 FY2026ended Mar 31, 2026filed Apr 28, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Jul 29, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 10, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,5571,6741,2731,5071,3661,2161,0531,179+14.0%
Cost of revenue10910510512199797388+9.8%
Gross profit—————————
Research and development1,792517516611507495437466+253.7%
Selling, general and administrative364352328390329331326327+10.7%
Operating income(708)698301336444530205302−259.7%
Other income (expense)16364782−71.1%
Pretax income(689)752344390482558234314−242.8%
Income tax9616640915815376113+65.0%
Net income(785)586303299424405158201−285.0%
Diluted EPS ($)(3.86)2.811.47—2.112.040.80—−282.9%
Diluted shares (millions)203208207—201199198——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Incyte Genomics Inc balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 28, 2026Q1 FY2026ended Mar 31, 2026filed Apr 28, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Jul 29, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 10, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents3,2763,9823,4613,0982,4551,9551,9421,688+33.4%
Short-term investments—————————
Total current assets5,5216,0275,4845,0244,2783,6443,5073,239+29.1%
Total assets7,2877,8737,3396,9586,3305,8215,7495,444+15.1%
Total current liabilities1,4381,3121,4901,5151,3391,2791,7201,642+7.4%
Long-term debt—————————
Total liabilities1,6441,5281,7161,7901,6791,6502,0821,997−2.1%
Stockholders’ equity5,6436,3445,6235,1674,6514,1713,6683,448+21.3%
Shares outstanding (millions)204203200199196195194194—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Incyte Genomics Inc cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 28, 2026Q1 FY2026ended Mar 31, 2026filed Apr 28, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Jul 29, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 10, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(675)50836954355945266381−220.7%
Capital expenditures—————————
Free cash flow (CFO − capex)—————————
Depreciation and amortization2426242424232223+0.6%
Share repurchases———00——0—
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 10, 2026.

Income statement

Incyte Genomics Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 10, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 7, 2023FY2021ended Dec 31, 2021filed Feb 8, 2022FY2020ended Dec 31, 2020filed Feb 9, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 17, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed May 3, 2011FY2009ended Dec 31, 2009filed May 3, 2011
Revenue5,1414,2413,6963,3952,9862,6672,1591,8821,5361,106754511355297941709
Cost of revenue372312255207151131114947958———————
Gross profit—————————————————
Research and development2,0502,6071,6281,5861,4582,2161,1541,1981,326582480348260210179124119
Selling, general and administrative1,3761,2421,1561,00274051746943436630319716611085583228
Operating income1,51561621579586(264)402129(243)14551(5)(16)1(143)14(140)
Other income (expense)251314(1)1123523217————————
Pretax income1,664317834529570(232)487115(312)1078(49)(83)(44)(187)(32)—
Income tax378284237188(378)63406131000———
Net income1,28733598341949(296)447109(313)104———————
Diluted EPS ($)6.410.152.651.524.27(1.36)2.050.51(1.53)0.540.03(0.29)(0.56)————
Diluted shares (millions)201211226224222218218216205194187168148—125122103

Balance sheet

Incyte Genomics Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 10, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 7, 2023FY2021ended Dec 31, 2021filed Feb 8, 2022FY2020ended Dec 31, 2020filed Feb 9, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 17, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed May 3, 2011FY2009ended Dec 31, 2009filed May 3, 2011
Cash and equivalents3,0981,6883,2132,9512,0571,5131,8331,164900652521452471224273418450
Short-term investments——44328829128828527427015618614838446—
Total current assets5,0243,2394,6454,0933,1192,3602,4811,8321,505994842680556310311455—
Total assets6,9585,4446,7825,8414,9333,5613,4272,6462,3031,6391,007796630330329490—
Total current liabilities1,5151,6421,2401,157854631513425375274168221108136136114—
Long-term debt———————19,09427750750841847410316293—
Total liabilities1,7901,9971,5921,4711,1639508287206721,219836878823505556578—
Stockholders’ equity5,1673,4485,1904,3703,7702,6112,5981,9261,631419171(82)(193)(175)(227)(89)(102)
Shares outstanding (millions)199194225223221220217214212189187172166134127125—

Cash flow statement

Incyte Genomics Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 10, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 7, 2023FY2021ended Dec 31, 2021filed Feb 8, 2022FY2020ended Dec 31, 2020filed Feb 9, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 14, 2017FY2015ended Dec 31, 2015filed Feb 12, 2016FY2014ended Dec 31, 2014filed Feb 17, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed May 3, 2011FY2009ended Dec 31, 2009filed May 3, 2011
Operating cash flow1,413335496970749(125)711336(93)30589——————
Capital expenditures———781811877873111120262843440
Free cash flow (CFO − capex)———892568(312)633263(204)18463——————
Depreciation and amortization9389836858525555525845412930272417
Share repurchases02,00500—————————————
Dividends paid—————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$8M
8 sales by 2 insiders; officers and directors $8M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$58M
47 sales by 10 insiders; officers and directors $58M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 15, 2026Cagnoni Pablo JPresident, Global Head of R&Doption exercise839$71.93$60K184,039Oct 19, 2026
Oct 15, 2026Cagnoni Pablo JPresident, Global Head of R&Doption exercise423$61.76$26K184,462Oct 19, 2026
Oct 15, 2026Cagnoni Pablo JPresident, Global Head of R&Doption exercise455$61.18$28K184,917Oct 19, 2026
Oct 15, 2026Cagnoni Pablo JPresident, Global Head of R&Doption exercise925$64.25$59K185,842Oct 19, 2026
Oct 15, 2026Cagnoni Pablo JPresident, Global Head of R&Dopen-market sale10b5-12,642$112.71$298K183,200Oct 19, 2026
Oct 1, 2026Heeson LeeEVP, Head of Incyte Intltax withholding463$117.14$54K37,578Oct 5, 2026
Sep 30, 2026Baker BROS. Advisors LP+5 moreDirector, 10% ownerawardindirect322$0.00—3MOct 2, 2026
Sep 30, 2026Baker BROS. Advisors LP+5 moreDirector, 10% ownerawardindirect322$0.00—28MOct 2, 2026
Sep 30, 2026Clancy Paul JDirectoraward203$121.35$25K25,838Oct 2, 2026
Sep 30, 2026Harrigan EdmundDirectoraward206$121.35$25K23,225Oct 2, 2026
Sep 22, 2026Gardner David HEVP, Chief Strategy Officertax withholding920$126.93$117K15,904Sep 24, 2026
Sep 15, 2026Cagnoni Pablo JPresident, Global Head of R&Doption exercise2,957$61.76$183K186,157Sep 17, 2026
Sep 15, 2026Cagnoni Pablo JPresident, Global Head of R&Doption exercise4,551$61.18$278K190,708Sep 17, 2026
Sep 15, 2026Cagnoni Pablo JPresident, Global Head of R&Doption exercise6,477$64.25$416K197,185Sep 17, 2026
Sep 15, 2026Cagnoni Pablo JPresident, Global Head of R&Doption exercise9,233$71.93$664K206,418Sep 17, 2026
Sep 15, 2026Cagnoni Pablo JPresident, Global Head of R&Dopen-market sale10b5-19,233$120.50$1M197,185Sep 17, 2026
Sep 15, 2026Cagnoni Pablo JPresident, Global Head of R&Dopen-market sale10b5-113,985$120.49$2M183,200Sep 17, 2026
Aug 25, 2026Basi Ramitpal KEVP, Human Resourcestax withholding504$129.72$65K10,993Aug 27, 2026
Aug 19, 2026Cagnoni Pablo JPresident, Global Head of R&Dopen-market sale10b5-110,801$125.56$1M183,200Aug 20, 2026
Aug 12, 2026Cagnoni Pablo JPresident, Global Head of R&Dopen-market sale10b5-110,803$120.04$1M194,001Aug 14, 2026
Aug 5, 2026Cagnoni Pablo JPresident, Global Head of R&Dopen-market sale10b5-110,640$122.69$1M204,804Aug 7, 2026
Aug 5, 2026Mayes Patrick AEVP & Chief Scientific Officeroption exercise2,207$106.47$235K63,648Aug 7, 2026
Aug 5, 2026Mayes Patrick AEVP & Chief Scientific Officeropen-market sale10b5-12,207$123.99$274K61,441Aug 7, 2026
Aug 3, 2026Mayes Patrick AEVP & Chief Scientific Officeroption exercise6,055$105.43$638K67,496Aug 4, 2026
Aug 3, 2026Mayes Patrick AEVP & Chief Scientific Officeropen-market sale10b5-16,055$120.43$729K61,441Aug 4, 2026

Full insider history for Incyte Genomics Inc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
INCYTE CORPORATION, CIK 879169 on EDGAR
Extract generated
November 1, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2023
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfRevenue
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/INCY.json